DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2788 INJURY THERAPY (Q2152847)

From EU Knowledge Graph
Revision as of 03:57, 3 November 2020 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair)
Jump to navigation Jump to search
Project Q2152847 in Italy
Language Label Description Also known as
English
DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2788 INJURY THERAPY
Project Q2152847 in Italy

    Statements

    0 references
    46,149.32 Euro
    0 references
    92,298.59 Euro
    0 references
    50.0 percent
    0 references
    10 November 2017
    0 references
    30 June 2021
    0 references
    UNIVERSITA' DEGLI STUDI DI TRIESTE
    0 references
    0 references

    45°40'37.52"N, 13°45'12.31"E
    0 references
    IL PRESENTE PROGETTO RIGUARDA LO SVILUPPO E IL TESTO IN VITRO E IN VIVO IN MODELLI PRE-CLINICI UN PRODOTTO TERAPEUTICO INNOVATIVO BASATO SULLA COMBINAZIONE DI TRE ELEMENTI (MATRICE EXTRACELLULARE, CELLULE ENDOTELIALI E FATTORI DI CRESCITA), UTILIZZANDO IL BIOREATTORE AUTOMATIZZATO NANT 001 AL FINE DI CONSENTIRE LA STANDARDIZZAZIONE DEL PROCESSO, NONCHé LA RIDUZIONE DI TEMPI E COSTI DEL PROCESSAMENTO DELLE CELLULE ENDOTELIALI AUTOLOGHE (ISOLATE DA UNA BIOPSIA DELLO STESSO PAZIENTE IN CUI VERRAN (Italian)
    0 references
    THIS PROJECT CONCERNS THE DEVELOPMENT AND THE IN VITRO AND IN VIVO MODELS IN PRE-CLINICAL MODELS OF AN INNOVATIVE THERAPEUTIC PRODUCT BASED ON THE COMBINATION OF THREE ELEMENTS (EXTRACELLULAR MATRIX, ENDOTHELIAL CELLS AND GROWTH DRIVERS), USING THE AUTOMATIC NANT 001 BIOREACTOR IN ORDER TO ALLOW STANDARDISATION OF THE PROCESS, AVOIDANCE OF TIME AND COST OF THE PROCESS OF AUTOLOGOUS ENDOTHELIAL CELLS (ISOLATED BY A PATIENT BIOPSY IN THE SAME PATIENT WHERE VERRAN (English)
    0 references

    Identifiers

    J96C17000240006
    0 references